Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Biothera Inc patents


Recent patent applications related to Biothera Inc. Biothera Inc is listed as an Agent/Assignee. Note: Biothera Inc may have other listings under different names/spellings. We're not affiliated with Biothera Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Biothera Inc-related inventors


Bispecific binding proteins

The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.. . ... Biothera Inc

Anti-ox40 antibodies and their uses

The present disclosure provides novel anti-ox40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Biothera Inc

Compositions and methods for treating neurological disorders

The present invention generally provides vectors, compositions, and methods of using the same for treating neurological disorders, including managing pain. The compositions and methods include the use of g protein-coupled receptors and ligand-gated ion channels to treat neurological indications including pain, epilepsy and satiety disorders. ... Biothera Inc

Methods and compositions for the prevention and treatment of disease

The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of col4a3, col4a4 and col4a5 genes. Also disclosed herein are methods of preventing or treating alport syndrome in a mammalian subject, reducing risk factors associated with alport syndrome, and/or reducing the likelihood or severity of alport syndrome. ... Biothera Inc

Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

The present disclosure provides populations of cells comprising partially mature and optimally activated dendritic cells that can be used for administration to individuals having a cancer and/or tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 10 to about 19 hours, upon administration efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. ... Biothera Inc

Anti-cd40 antibodies and their uses

The present disclosure provides novel anti-cd40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Biothera Inc

Allogenic tumor cell vaccine

The described invention provides a tumor cell vaccine comprising genetically modified tumor cell line of a particular tumor type that stably expresses high levels of two or more immunomodulators. According to some embodiments, an immunogenic amount of the tumor cell line variants may be selected for concomitant expression of two or more of recombinant membrane expressed igg1, cd40l, tnf-alpha, as well as membrane and soluble forms of gm-csf, and flt-3l peptides that are effective to elicit an anti-tumor immune response compared to the parent unmodified tumor cell line as measured in vitro by a one-way mixed lymphocyte tumor reaction assay using human peripheral blood mononuclear cells and the genetically modified allogeneic cell vaccine candidate. ... Biothera Inc

Chimeric cytokine formulations for ocular delivery

Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.. . ... Biothera Inc

Compositions and methods for treating cancer with arginine depletion and immuno oncology agents

Methods of treating tumors or cancer include administration of an arginine depleting enzyme and an immune-oncology agent.. . ... Biothera Inc

Anti-ox40 antibodies and their uses

The present disclosure provides novel anti-ox40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Biothera Inc

Fusion proteins for inhibiting angiogenesis

The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.. ... Biothera Inc

Selective surfaces for, and methods of, selecting a population of stem and progenitor cells, and uses thereof

The present invention discloses selective surfaces, wherein said selective surfaces comprise a biocompatible polymer comprising maleic anhydride molecules and an apoptosis inducing ligand bound to the maleic anhydride molecules. The invention also encompasses devices and kits comprising the selective surface and methods for its production. ... Biothera Inc

Sirp polypeptide compositions and methods of use

Provided herein are sirp-gamma, sirp-beta or sirp-beta2 decoy polypeptides for immunotherapy and/or treatment of cancer, anemia, transplant, asthma, allergy, auto-immune disease, and viral infection.. . ... Biothera Inc

Delivering crispr therapeutics with lipid nanoparticles

The present invention provides lipid particles comprising therapeutic nucleic acids such as grna that target gene expression.. . ... Biothera Inc

05/31/18 / #20180148711

Genome editing vectors

The present invention generally provides hsv-based genome editing vectors, cell-based compositions, and methods of using the same.. . ... Biothera Inc

05/31/18 / #20180148513

Anti-pd-1 antibodies and their uses

The present disclosure provides novel anti-pd-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Biothera Inc

05/31/18 / #20180148482

Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof

The present disclosure provides immunogenic compositions useful in prevention and treatment of staphylococcus aureus infection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. ... Biothera Inc

05/31/18 / #20180147251

Methods and compositions for the prevention or treatment of barth syndrome

The disclosure provides methods of preventing or treating barth syndrome in a mammalian subject, reducing risk factors associated with barth syndrome, and/or reducing the likelihood or severity of barth syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of taz1 in subjects in need thereof.. ... Biothera Inc

05/24/18 / #20180142035

Compositions and methods for treatment of cancer

Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.. . ... Biothera Inc

05/24/18 / #20180141981

Immunogenic composition comprising engineered alpha-hemolysin oligopeptides

The present disclosure provides immunogenic compositions useful in prevention and treatment of staphylococcus aureus infection. In particular, the present disclosure provides methods of inducing an immune response against an alpha-hemolysin-expressing s. ... Biothera Inc

05/17/18 / #20180135131

Neuroendocrine tumors

The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (ffpe) samples.. . ... Biothera Inc

05/10/18 / #20180128836

Beta-glucan assay methods

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to β-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-β-glucan antibody compared to a reference standard, computing a relative antibody unit (rau) value for anti-β-glucan antibody in the sample, and identifying the subject as biomarker positive if the rau value is greater than a predetermined rau value for the biomarker anti-β-glucan antibody.. ... Biothera Inc

05/10/18 / #20180127715

Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aapcs) are disclosed, including aapcs comprising a myeloid cell transduced with one or more viral vectors, such as a molm-14 or a em-3 myeloid cell, wherein the myeloid cell endogenously expresses hla-ab/c, icos-l, and cd58, and wherein the one or more viral vectors comprise a nucleic acid encoding cd86 and a nucleic acid encoding 4-1bbl and/or ox40l and transduce the myeloid cell to express cd86 and 4-1bbl and/or ox40l proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (tils) with aapcs and methods of treating cancers using tils after expansion with aapcs are also disclosed.. ... Biothera Inc

05/10/18 / #20180127506

Dac hyp compositions and methods

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.. . ... Biothera Inc

05/03/18 / #20180117112

Methods for performing a coronary artery bypass graft procedure

The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.. ... Biothera Inc

04/12/18 / #20180099107

Two-stage apparatus and method for generating and concentrating fine particle aerosols

A system and a method for generating a respirable dry powder aerosol (15) from a liquid solution or liquid suspension at a respirable dry powder aerosol volume flow (91). A liquid aerosol generating nozzle (3) generates from the liquid solution or liquid suspension a liquid aerosol (13) that is diluted by dilution gas (4) and dried in a cylindrical evaporation chamber (6) to generate a dry powder aerosol (14) that is subsequently concentrated by a cylindrical single linear slit aerosol concentrator (9). ... Biothera Inc

04/12/18 / #20180099106

Apparatus and method for generating and concentrating fine particle aerosols

A system and a method for generating a respirable dry powder aerosol (15) from a liquid solution or liquid suspension at a respirable dry powder aerosol volume flow (91). A liquid aerosol generating nozzle (3) generates from the liquid solution or liquid suspension a liquid aerosol (13) that is diluted by dilution gas (4) and dried in a cylindrical evaporation chamber (6) to generate a dry powder aerosol (14) that is subsequently concentrated by a cylindrical single linear slit aerosol concentrator (9). ... Biothera Inc

04/05/18 / #20180092848

Novel lipid formulations for nucleic acid delivery

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Biothera Inc

03/29/18 / #20180085312

Novel lipid formulations for nucleic acid delivery

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Biothera Inc

03/22/18 / #20180079820

Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies

The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (naflds) and/or nonalcoholic steatohepatitis (nash) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing nafld/nash using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor.. ... Biothera Inc

03/15/18 / #20180073085

Determining tumor origin

The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (ffpe) samples.. . ... Biothera Inc

03/15/18 / #20180072810

Anti-pd-1 antibodies and their uses

The present disclosure provides novel anti-pd-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Biothera Inc

03/15/18 / #20180072809

Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. ... Biothera Inc

03/15/18 / #20180071397

Novel lipid formulations for delivery of therapeutic agents to solid tumors

The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (e.g., one or more interfering rna molecules), methods of making the snalp, and methods of delivering and/or administering the snalp (e.g., for the treatment of cancer). ... Biothera Inc

02/15/18 / #20180044378

Processes for preparing pharmaceutically relevant peptides

The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is d-arg-2′6′-dmt-lys-phe-nh2.. ... Biothera Inc

01/25/18 / #20180023053

Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells

Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.. ... Biothera Inc

01/25/18 / #20180022821

Compositions and methods for tumor transduction

The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.. . ... Biothera Inc

01/18/18 / #20180016583

Compositions and methods for silencing hepatitis b virus gene expression

The present invention provides compositions comprising therapeutic nucleic acids such as sirna that target hepatitis b virus (hbv) gene expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating hbv infection and/or hdv infection in humans).. . ... Biothera Inc

12/28/17 / #20170369842

Differentiation of primate pluripotent stem cells to hematopoietic lineage cells

The invention provides methods of differentiating primate pluripotent stem cells into cells of hematopoietic lineage. The invention further provides hematopoietic lineage cells differentiated from primate pluripotent stem cells, as well as methods of using the same and kits comprising the same.. ... Biothera Inc

12/28/17 / #20170368061

Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof

Ophthalmic formulations containing tyrosine kinase inhibitors, such as nintedanib, axitinib, sorafenib, and pazopanib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. ... Biothera Inc

12/21/17 / #20170363625

Quality assays for antigen presenting cells

The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of t cells and for presentation of predetermined antigen by apcs are provided.. ... Biothera Inc

12/21/17 / #20170360902

Pharmaceutical composition comprising plasminogen and uses thereof

Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a ph of about 3.0 to about 10.0. ... Biothera Inc

12/14/17 / #20170355781

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)

The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein ceacam1 and optionally binds also other subtypes of the ceacam protein family. Disclosed antibodies and antibody fragments are characterized by specific cdr sequences. ... Biothera Inc

12/14/17 / #20170354728

Antigen specific multi epitope-based anti-infective vaccines

The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class ii and class i-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. ... Biothera Inc

12/07/17 / #20170348429

Anti-cmet antibody drug conjugates and methods for their use

The present disclosure provides antibody drug conjugates that bind human cmet, their methods of making, and their uses to treat patients having cancer.. . ... Biothera Inc

11/30/17 / #20170342169

Bispecific binding proteins

The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.. . ... Biothera Inc

11/30/17 / #20170342159

Anti-cd40 antibodies and their uses

The present disclosure provides novel anti-cd40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.. . ... Biothera Inc

11/30/17 / #20170342150

Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Compositions and methods for treating mm are provided herein.. . ... Biothera Inc

11/30/17 / #20170340695

Methods and compositions for the prevention and treatment neuropathy

The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.. ... Biothera Inc

11/30/17 / #20170340266

Therapeutic angiogenesis for treating erectile conditions

Disclosed are devices, methods and surgical procedures for detecting, imaging, analyzing, diagnosing and/or treating vascular disorders and related conditions of the human and mammalian body in males and/or females. In particular embodiments, treatments include methods for imaging, analyzing and improving erectile dysfunction and related conditions and potentially increasing angiogenesis in response to specifically diagnosed conditions.. ... Biothera Inc

11/23/17 / #20170335007

Anti-cd39 antibodies and uses thereof

The present disclosure relates generally to anti-cd39 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.. . ... Biothera Inc

11/16/17 / #20170326197

Methods and compositions for preventing or treating ophthalmic conditions

The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.. ... Biothera Inc

11/09/17 / #20170319647

Combination therapies using cyclosporine and aromatic cationic peptides

The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or more additional active agents such as cyclosporine.. ... Biothera Inc

10/26/17 / #20170304352

Glucan preparations

Particulate β-glucan is solubilized at elevated pressure and temperature to form soluble β-glucan. The method is safe and economical and produces a product that is an improved pharmaceutical agent.. ... Biothera Inc

10/05/17 / #20170286596

Identification of tumors and tissues

The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (ffpe) samples.. . ... Biothera Inc

09/28/17 / #20170275287

Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof

Compounds as immune system modulators bearing a pteridine core are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing autoimmunity disease using the same are described.. ... Biothera Inc

09/21/17 / #20170268064

Identification of tumors

The invention provides methods for the use of gene expression measurements to classify or identify tumors in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (ffpe) samples.. . ... Biothera Inc

09/21/17 / #20170266279

Compositions including beta-glucans and method of use

The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a tlr agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen. ... Biothera Inc

09/14/17 / #20170260523

Non-liposomal systems for nucleic acid delivery

The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Biothera Inc

09/14/17 / #20170260288

Compositions and methods for tumor transduction

The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.. . ... Biothera Inc

09/14/17 / #20170258719

Liposomal apparatus and manufacturing methods

The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. ... Biothera Inc

08/31/17 / #20170247461

Dac hyp compositions

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.. . ... Biothera Inc

08/24/17 / #20170240641

Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

The present disclosure relates to methods for treating type 1 diabetes (t1d) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating t1d using substantially lower doses of insulin supple-mentation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor.. ... Biothera Inc

08/24/17 / #20170240593

Aromatic-cationic peptides and uses of same

The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport and electrical conductance.. ... Biothera Inc

08/17/17 / #20170233481

Anti-cd25 antibodies and their uses

The present disclosure relates to antibodies directed to cd25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.. . ... Biothera Inc

08/17/17 / #20170233459

Systems and methods for the production of human polyclonal antibodies

Disclosed herein is a method for producing human antibodies against a pathogen comprising injecting a non-human animal with a pathogen-derived dna vaccine in at least two locations of the animal; injecting the animal with an adjuvant in a location of the animal different from the location of the dna vaccine location; collecting plasma from the animal after the injections; and purifying polyclonal antibody from the plasma.. . ... Biothera Inc

08/10/17 / #20170224740

Methods for treating nervous system injury and disease

. . The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as tse cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as amp cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or accs), each alone or in combination with each other and/or other agents.. ... Biothera Inc

08/03/17 / #20170218016

Aromatic-cationic peptides and uses of same

Disclosed herein are compositions and methods related to aromatic-cationic peptides. In particular, the compositions and methods relate to aromatic-cationic peptides in conjunction with cytochrome c.. ... Biothera Inc

08/03/17 / #20170216367

Treatment of diseases and conditions caused by increased vascular permeability

The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. ... Biothera Inc

07/27/17 / #20170209498

Methods for treating ocular contusion and blunt injury and traumatic injury of the optic nerve

The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions amnion-derived cellular cytokine solution (accs), including novel immediate-release, targeted-release, and sustained-release (sr) accs compositions (referred to herein as “sr-accs” compositions) and/or and amnion-derived multipotent progenitor (amp) cell compositions. ... Biothera Inc

07/20/17 / #20170202919

Methods for preventing or treating optic neuritis

The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. ... Biothera Inc

07/13/17 / #20170196933

Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. ... Biothera Inc

06/22/17 / #20170174753

Method for treating breast cancer

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of tsm, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to tsm and uses of the same. Breast cancer cells lacking er protein expression, pgr protein expression and/or showing absence of her2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-kaag1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to kaag1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. ... Biothera Inc

06/15/17 / #20170166637

Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy

The present invention provides compositions comprising anti-ceacam1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between pd-1 and its ligands, and methods for their combined use in treating cancer.. . ... Biothera Inc

06/08/17 / #20170158753

Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species

The disclosure provides binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.. . ... Biothera Inc

06/01/17 / #20170152540

Compositions and methods for producing glycoproteins

The present disclosure relates to methods of producing antibodies with increased levels of non-fucosylated glycoforms by culturing mammalian cells in culture media with enhanced concentrations of glycine relative to traditional basal media.. . ... Biothera Inc

06/01/17 / #20170151344

Anti-hulrrc15 antibody drug conjugates and methods for their use

The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human lrrc15, their methods of making, and their uses to treat patients having cancer.. . ... Biothera Inc

06/01/17 / #20170151343

Anti-hulrrc15 antibody drug conjugates and methods for their use

The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human lrrc15, their methods of making, and their uses to treat patients having cancer.. . ... Biothera Inc

06/01/17 / #20170151333

Novel cationic lipids and methods of use thereof

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. ... Biothera Inc

05/18/17 / #20170137891

Integration of tumor characteristics with breast cancer index

Methods of determining risk of recurrence of a breast cancer of a subject are provided. Also provided are methods of predicting responsiveness to a therapy of a breast cancer of a subject. ... Biothera Inc

05/18/17 / #20170137786

Enhanced adoptive cell therapy

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. ... Biothera Inc

05/18/17 / #20170136101

Methods for preventing and/or treating nasal polyps and rhinosinusitis

The invention is directed to methods for preventing and/or treating nasal polyps. The invention is further directed to methods for preventing and/or treating rhinosinusitus. ... Biothera Inc

05/04/17 / #20170119762

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.. ... Biothera Inc

04/13/17 / #20170101657

Methods of ganglioside production

The invention provides methods for production of gangliosides, e.g., gm1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., gm1, in the cells. ... Biothera Inc

04/13/17 / #20170100425

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.. ... Biothera Inc

04/13/17 / #20170100424

Beta-glucan methods and compositions that affect the tumor microenvironment

This disclosure relates to the combination of soluble β-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.. ... Biothera Inc

03/23/17 / #20170081363

Pharmaceutically relevant aromatic-cationic peptides

The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is 2′6′-dmt-d-arg-phe-lys-nh2 or phe-d-arg-phe-lys-nh2.. ... Biothera Inc

03/16/17 / #20170072036

Antigen specific multi epitope vaccines

The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple mhc class i and class ii epitopes which are highly abundant in the population. ... Biothera Inc

03/02/17 / #20170058012

Novel glycosaminoglycan-antagonising fusion proteins and methods of using same

The present invention relates to novel monomeric fusion proteins derived from human gag binding proteins such as chemokines with increased glycosaminoglycan (gag) binding affinity and knocked-out or reduced gpcr activity compared to wild type gag binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.. . ... Biothera Inc

02/16/17 / #20170044270

Humanized antibodies against ceacam1

Humanized antibodies, capable of specific binding to human ceacam1 molecules containing human-to-murine back-mutations in non-cdr variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.. ... Biothera Inc

02/16/17 / #20170042814

Novel lipid formulations for nucleic acid delivery

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (snalp) comprising a nucleic acid (such as one or more interfering rna), methods of making the snalp, and methods of delivering and/or administering the snalp.. ... Biothera Inc

02/09/17 / #20170035812

Novel cell-derived composition

The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed amnion-derived cellular cytokine solution-b (accs-b). ... Biothera Inc

02/02/17 / #20170028015

Methods for performing a coronary artery bypass graft procedure

The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.. ... Biothera Inc

02/02/17 / #20170027210

Yeast cell wall enriched in mannan oligosaccharide protein

The present invention relates to yeast cell wall 5 compositions enriched with mannose, mannose extracts and processes for making the same.. . ... Biothera Inc

01/12/17 / #20170007702

Trialkyl cationic lipids and methods of use thereof

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. ... Biothera Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Biothera Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Biothera Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###